Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 3/20 | 0.35 |
| ▸ | LDHB | P07195 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31180749 | 1.00 | HDAC1 (0.43) | HDAC1HDAC2HDAC8NAMPTRAB9A | |
| SCHEMBL30125660 | 0.96 | NAMPT (0.42) | HDAC1HDAC2HDAC8NAMPTLDHA | |
| SCHEMBL25707625 | 0.92 | HDAC1 (0.55) | HDAC1HDAC2HDAC8NAMPTPOLB | |
| SCHEMBL23728551 | 0.91 | HDAC1 (0.56) | HDAC1HDAC2HDAC8NAMPTPOLB | |
| SCHEMBL31180736 | 0.90 | HDAC1 (0.42) | HDAC1HDAC2HDAC8NAMPTRAB9A | |
| SCHEMBL30125641 | 0.90 | HDAC1 (0.42) | HDAC1HDAC2HDAC8NAMPTRAB9A | |
| SCHEMBL23728853 | 0.89 | HDAC1 (0.57) | HDAC1HDAC2HDAC8NAMPTPOLB | |
| SCHEMBL25248804 | 0.89 | HDAC1 (0.59) | HDAC1HDAC2HDAC8NAMPTPOLB | |
| SCHEMBL31180737 | 0.89 | HDAC1 (0.42) | HDAC1HDAC2HDAC8NAMPTRAB9A | |
| SCHEMBL30125691 | 0.87 | HDAC1 (0.61) | HDAC1HDAC2HDAC8POLBERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. | 2024-10-31 | — | — | US | disclosed |
| EP-4384506-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023014793-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | POLI, POLR2A, POLR2B | HDAC1 489/4885HDAC2 551/4885HDAC8 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.